Cargando…
Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines
The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018) with other recently published guidelines for treating bipolar disorder. We reviewed a total of five recently published global treatment guidelines and compar...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Neuropsychopharmacology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478090/ https://www.ncbi.nlm.nih.gov/pubmed/30905116 http://dx.doi.org/10.9758/cpn.2019.17.2.155 |
_version_ | 1783413126718291968 |
---|---|
author | Jeong, Jong-Hyun Bahk, Won-Myong Woo, Young Sup Lee, Jung Goo Kim, Moon-Doo Sohn, InKi Shim, Se-Hoon Jon, Duk-In Seo, Jeong Seok Kim, Won Song, Hoo-Rim Min, Kyung Joon Yoon, Bo-Hyun |
author_facet | Jeong, Jong-Hyun Bahk, Won-Myong Woo, Young Sup Lee, Jung Goo Kim, Moon-Doo Sohn, InKi Shim, Se-Hoon Jon, Duk-In Seo, Jeong Seok Kim, Won Song, Hoo-Rim Min, Kyung Joon Yoon, Bo-Hyun |
author_sort | Jeong, Jong-Hyun |
collection | PubMed |
description | The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018) with other recently published guidelines for treating bipolar disorder. We reviewed a total of five recently published global treatment guidelines and compared treatment recommendation of the KMAP-BP 2018 with those of other guidelines. For initial treatment of mania, there were no significant differences across treatment guidelines. All guidelines recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy or a combination of an MS with an AAP as a first-line treatment strategy for mania. However, the KMAP-BP 2018 did not prefer monotherapy with MS or AAP for psychotic mania. Quetiapine, olanzapine and aripiprazole were the first-line AAPs for nearly all phases of bipolar disorder across guidelines. Most guidelines advocated newer AAPs as first-line treatment options for all phases while lamotrigine was recommended for depressive and maintenance phases. Lithium and valproic acid were commonly used as MSs in all phases of bipolar disorder. As research evidence accumulated over time, recommendations of newer AAPs (such as asenapine, cariprazine, paliperidone, lurasidine, long-acting injectable risperidone and aripiprazole once monthly) became prominent. KMAP-BP 2018 guidelines were similar to other guidelines, reflecting current changes in prescription patterns for bipolar disorder based on accumulated research data. Strong preference for combination therapy was characteristic of KMAP-BP 2018, predominantly in the treatment of psychotic mania and severe depression. Further studies were needed to address several issues identified in our review. |
format | Online Article Text |
id | pubmed-6478090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean College of Neuropsychopharmacology |
record_format | MEDLINE/PubMed |
spelling | pubmed-64780902019-05-07 Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines Jeong, Jong-Hyun Bahk, Won-Myong Woo, Young Sup Lee, Jung Goo Kim, Moon-Doo Sohn, InKi Shim, Se-Hoon Jon, Duk-In Seo, Jeong Seok Kim, Won Song, Hoo-Rim Min, Kyung Joon Yoon, Bo-Hyun Clin Psychopharmacol Neurosci Review The objective of this study was to compare recommendations of the Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018) with other recently published guidelines for treating bipolar disorder. We reviewed a total of five recently published global treatment guidelines and compared treatment recommendation of the KMAP-BP 2018 with those of other guidelines. For initial treatment of mania, there were no significant differences across treatment guidelines. All guidelines recommended mood stabilizer (MS) or atypical antipsychotic (AAP) monotherapy or a combination of an MS with an AAP as a first-line treatment strategy for mania. However, the KMAP-BP 2018 did not prefer monotherapy with MS or AAP for psychotic mania. Quetiapine, olanzapine and aripiprazole were the first-line AAPs for nearly all phases of bipolar disorder across guidelines. Most guidelines advocated newer AAPs as first-line treatment options for all phases while lamotrigine was recommended for depressive and maintenance phases. Lithium and valproic acid were commonly used as MSs in all phases of bipolar disorder. As research evidence accumulated over time, recommendations of newer AAPs (such as asenapine, cariprazine, paliperidone, lurasidine, long-acting injectable risperidone and aripiprazole once monthly) became prominent. KMAP-BP 2018 guidelines were similar to other guidelines, reflecting current changes in prescription patterns for bipolar disorder based on accumulated research data. Strong preference for combination therapy was characteristic of KMAP-BP 2018, predominantly in the treatment of psychotic mania and severe depression. Further studies were needed to address several issues identified in our review. Korean College of Neuropsychopharmacology 2019-03 2019-04-30 /pmc/articles/PMC6478090/ /pubmed/30905116 http://dx.doi.org/10.9758/cpn.2019.17.2.155 Text en Copyright © 2019, Korean College of Neuropsychopharmacology This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Jeong, Jong-Hyun Bahk, Won-Myong Woo, Young Sup Lee, Jung Goo Kim, Moon-Doo Sohn, InKi Shim, Se-Hoon Jon, Duk-In Seo, Jeong Seok Kim, Won Song, Hoo-Rim Min, Kyung Joon Yoon, Bo-Hyun Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines |
title | Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines |
title_full | Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines |
title_fullStr | Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines |
title_full_unstemmed | Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines |
title_short | Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines |
title_sort | korean medication algorithm for bipolar disorder 2018: comparisons with other treatment guidelines |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478090/ https://www.ncbi.nlm.nih.gov/pubmed/30905116 http://dx.doi.org/10.9758/cpn.2019.17.2.155 |
work_keys_str_mv | AT jeongjonghyun koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT bahkwonmyong koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT wooyoungsup koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT leejunggoo koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT kimmoondoo koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT sohninki koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT shimsehoon koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT jondukin koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT seojeongseok koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT kimwon koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT songhoorim koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT minkyungjoon koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines AT yoonbohyun koreanmedicationalgorithmforbipolardisorder2018comparisonswithothertreatmentguidelines |